Welcome to Vayuna Therapeutics
Vayuna Therapeutics is developing precision medications derived from nature's most potent plants to target treatment-resistant cancers within genomically defined patient populations
FIRST-IN-CLASS
Next-Generation Precision
ADCs and Parenteral Formulations with V-001
for EGFR High
& Treatment-Resistant Cancers
THE PROBLEM
Treatment Resistance in Cancer
Limited effective therapies for treatment-resistant solid tumors.
“EGFR High” expression occurs in 30–45% of breast cancers and up to 80% of solid tumors, while PIK3CA mutations appear in 30–40% of breast cancers and 10–15% of all cancers—driving PI3K overactivation and treatment resistance across tumor types.
Existing treatments are imprecise, resulting in suboptimal outcomes and significant toxicity.
the solution
Superior Efficacy
V-001 outperforms standards of care in NCI-60 screen, targeting PIK3CA-mutated and resistant cancers
EGFR/HER-2 directed ADCs
Precision delivery of V-001 payload for enhanced therapeutic effect.
Parenteral Formulations:
Systemic treatment for advanced & metastatic PIK3CA-mutated cancers.
Biomarker-Driven
Precision targeting for better outcomes, reduced toxicity and personalized care.
